US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares Pioneer Asset-Based Income ETF

25.17

0.0000

Post-market: 25.300.1300+0.52%16:04 EDT

Volume:113.00

Turnover:2.86K

Market Cap:54.74M

PE:- -

High:25.17

Open:25.17

Low:25.17

Close:25.17

52wk High:25.27

52wk Low:25.02

Shares:2.18M

Float Shares:2.18M

Volume Ratio:12.56

T/O Rate:0.01%

Dividend:0.10

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

AIA: "Business at architecture firms remains soft" in July

Calculated Risk

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Interim Results for ABI-6250

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABI\",,,,,undefined,":{"symbol":"ABI","market":"US","secType":"STK","nameCN":"VictoryShares Pioneer Asset-Based Income ETF","latestPrice":25.17,"timestamp":1756929600000,"preClose":25.17,"halted":0,"volume":113,"hourTrading":{"tag":"盘后","latestPrice":25.3,"preClose":25.17,"latestTime":"16:04 EDT","volume":2,"amount":50.6,"timestamp":1756929850855},"delay":0,"floatShares":2175000,"shares":2175000,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"09-03 18:27:52 EDT","open":25.17,"high":25.17,"low":25.17,"amount":2858.965,"amplitude":0,"askPrice":31.61,"askSize":200,"bidPrice":18.97,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1756944000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":25.17,"sharesOutstanding":2175000,"nav":25.236037,"aum":54888300,"dividendRate":0.003973,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.3,"preClose":25.17,"latestTime":"16:04 EDT","volume":2,"amount":50.6,"timestamp":1756929850855},"volumeRatio":12.555514},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABI\",,,,,undefined,":{"symbol":"ABI","floatShares":2175000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":12.555514,"shares":2175000,"dividePrice":0.1,"high":25.17,"amplitude":0,"preClose":25.17,"low":25.17,"week52Low":25.02483,"pbRate":"--","week52High":25.27,"institutionHeld":0,"latestPrice":25.17,"eps":0,"divideRate":0.003973,"volume":113,"delay":0,"ttmEps":0,"open":25.17,"prevYearClose":25.08,"prevWeekClose":25.17,"prevMonthClose":25.17,"prevQuarterClose":25.08,"fiveDayClose":25.17,"twentyDayClose":25.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABI\",params:#limit:5,,,undefined,":[{"date":"2025-08-06","symbol":"ABI","amount":0.083425,"announcedDate":"2025-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-06","defaultRemindTime":1754487000000,"name":"VictoryShares Pioneer Asset-Based Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-07","payableDate":"2025-08-06","currency":"USD","dateTimestamp":1754452800000,"payDate":"2025-08-07"},{"date":"2025-07-10","symbol":"ABI","amount":0.01517,"announcedDate":"2025-07-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-10","defaultRemindTime":1752154200000,"name":"VictoryShares Pioneer Asset-Based Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-11","payableDate":"2025-07-10","currency":"USD","dateTimestamp":1752120000000,"payDate":"2025-07-11"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABI\",market:\"US\",,,undefined,":[{"executeDate":"2025-07-10","recordDate":"2025-07-10","paymentDate":"2025-07-11","value":0.01517,"currency":"USD"},{"executeDate":"2025-08-06","recordDate":"2025-08-06","paymentDate":"2025-08-07","value":0.083425,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2560107061","title":"AIA: \"Business at architecture firms remains soft\" in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2560107061","media":"Calculated Risk","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560107061?lang=en_us&edition=fundamental","pubTime":"2025-08-20 11:34","pubTimestamp":1755660840,"startTime":"0","endTime":"0","summary":"From the AIA: ABI July 2025: Business at architecture firms remains softThe AIA/Deltek Architecture Billings Index  score for the month was below 50 for 31 out of the last 34 months, with a score of 46.2, as a majority of firms are still seeing declining billings. There are signs of hope ahead, as inquiries into new work grew slowly but steadily this month, following a brief three-month pause earlier this year. However, the value of newly signed design contracts at firms declined again in July, as firms continue to struggle to convert inquiries into contracts for new projects. This has been an issue for nearly as long as billings have been declining and reflects how soft business has been at many firms over the last two and a half years.This index usually leads CRE investment by 9 to 12 months, so this index suggests a slowdown in CRE investment throughout 2025 and into 2026.Multi-family billings have been below 50 for36 consecutive months.This suggests we will some further weakness in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.calculatedriskblog.com/2025/08/aia-business-at-architecture-firms.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"calculatedriskblog_highlight","symbols":["AIA","CRE","BK4087","ABI"],"gpt_icon":0},{"id":"2557521710","title":"Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes","url":"https://stock-news.laohu8.com/highlight/detail?id=2557521710","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557521710?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:00","pubTimestamp":1754654400,"startTime":"0","endTime":"0","summary":"– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350mg weekly oral dose compared to placebo over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/08/3130113/16259/en/Assembly-Biosciences-Reports-Positive-Interim-Results-from-Phase-1b-Clinical-Study-of-Long-Acting-Helicase-Primase-Inhibitor-Candidate-ABI-5366-Showing-Reductions-in-Viral-Shedding.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ASMB","BK4588","BK4181","HDV","PK","BK4139","BK4213","SD","ABI","BK4218"],"gpt_icon":0},{"id":"2557307420","title":"Assembly Biosciences Reports Interim Results for ABI-6250","url":"https://stock-news.laohu8.com/highlight/detail?id=2557307420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557307420?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:39","pubTimestamp":1754512782,"startTime":"0","endTime":"0","summary":"An update from Assembly Biosciences ( ($ASMB) ) is now available. On August 6, 2025, Assembly Biosciences announced interim results from their Phas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/assembly-biosciences-reports-interim-results-for-abi-6250?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/assembly-biosciences-reports-interim-results-for-abi-6250?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASMB","BK4139","ABI"],"gpt_icon":0},{"id":"2557077723","title":"Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2557077723","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557077723?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:05","pubTimestamp":1754510700,"startTime":"0","endTime":"0","summary":"– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128674/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1a-Data-from-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI-6250-for-Hepatitis-Delta-Virus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4599","ASMB","HDV","PK","ABI","ALT","LU1878469433.USD","BK4218","BK4181","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ABI\",params:#limit:6,delay:false,,,undefined,":[]}}